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The intracellular pathogen Listeria monocytogenes escapes from a phagosomal compartment into the cytosol
by secreting the pore-forming cytolysin listeriolysin O (LLO). During the proliferation of L. monocytogenes
bacteria in the mammalian cell cytosol, the secreted LLO is targeted for degradation by the ubiquitin system.
We report here that LLO is a substrate of the ubiquitin-dependent N-end rule pathway, which recognizes LLO
through its N-terminal Lys residue. Specifically, we demonstrated by reverse-genetic and pharmacological
methods that LLO was targeted for degradation by the N-end rule pathway in reticulocyte extracts and mouse
NIH 3T3 cells and after its secretion by intracellular bacteria into the mouse cell cytosol. Replacing the
N-terminal Lys of LLO with a stabilizing residue such as Val increased the in vivo half-life of LLO but did not
strongly affect the intracellular growth or virulence of L. monocytogenes. Nevertheless, this replacement
decreased the virulence of L. monocytogenes by nearly twofold, suggesting that a destabilizing N-terminal
residue of LLO may stem from positive selection during the evolution of this and related bacteria. A double
mutant strain of L. monocytogenes in which upregulated secretion of LLO was combined with a stabilizing
N-terminal residue was severely toxic to infected mammalian cells, resulting in reduced intracellular growth
of bacteria and an 100-fold-lower level of virulence. In summary, we showed that LLO is degraded by the
N-end rule pathway and that the degradation of LLO can reduce the toxicity of L. monocytogenes during
infection, a property of LLO that may have been selected for its positive effects on fitness during the evolution
of L. monocytogenes.
Listeria monocytogenes is a gram-positive, facultative, intra-
cytosolic bacterial pathogen of humans and animals. In hu-
mans, L. monocytogenes infections are typically food borne and
cause an invasive, sometimes fatal, disease in pregnant women,
the elderly, newborns, and immunocompromised individuals
(51, 66). Following internalization into mammalian cells, bac-
teria are initially contained within host vacuoles but rapidly
escape into the cytosol, largely through the perforation of the
phagosomal membrane by the pore-forming toxin called lis-
teriolysin O (LLO) (46, 66). LLO is an essential virulence
factor, as hly bacteria, which lack LLO, fail to escape from
the phagosomal compartment and are attenuated 10,000-fold
in comparison to their wild-type counterparts in the murine
model of listeriosis (20, 33, 45, 46). Once in the host cytosol, L.
monocytogenes cells grow and divide, exploiting a host mecha-
nism of actin-based motility to move within the cytosol and to
spread from cell to cell through the formation of long plasma
membrane extensions that are taken up by neighboring cells
(18, 34, 61). LLO is also required for productive cell-to-cell
spread because it facilitates the disruption of bacterium-con-
taining double-membrane vesicles within the secondarily in-
fected cells (23).
LLO is a member of a large family of toxins, called choles-
terol-dependent cytolysins, that are secreted by gram-positive
bacterial pathogens (1, 62). Secreted toxin monomers bind
cholesterol-containing membranes, oligomerize, and thereaf-
ter insert themselves into the membranes, forming pores of up
to 30 nm in diameter (62). While LLO is essential for phago-
somal escape and cell-to-cell spread in most cell types, its
membrane-perforating activity is potentially cytotoxic and
must be tightly regulated in order for L. monocytogenes to
remain in its intracellular replicative niche. Indeed, there is an
inverse correlation between toxicity and virulence: the more
toxic an L. monocytogenes strain is to an infected cell, the less
virulent it is in terms of its ability to spread the infection (24).
An inappropriately high level of activity of LLO in the host
cytosol results in plasma membrane perforation and lysis of the
host cell (16, 24, 25). The subsequent exposure of L. monocy-
togenes to the host’s extracellular defenses, particularly neutro-
phils, leads to decreased virulence (24).
LLO activity is controlled by several posttranscriptional
mechanisms that include an acidic pH optimum for LLO pore
formation (25), translational regulation of LLO synthesis (52),
and host-mediated degradation of LLO in the cytosol (53, 68).
Together, these mechanisms functionally overlap to limit LLO
activity during the growth of L. monocytogenes in the host
cytosol. For example, double mutations in LLO that compro-
mise both the acidic pH optimum and translational regulation
cause much greater host cell toxicity than either mutation
alone (24, 25, 52, 53). In addition, the host cell toxicity of LLO
from L. monocytogenes mutants with upregulated LLO trans-
lation is greatly increased when the host 26S proteasome is
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inhibited by pharmacological agents, a treatment that makes
the normally short-lived LLO a longer-lived protein (16, 52, 53,
68). Surprisingly, however, the inhibition of the proteasome
alone (in the absence of enhanced LLO synthesis) does not
result in significantly increased cytotoxicity (53).
The secreted LLO is destroyed in the cytosol by the ubiq-
uitin (Ub)-proteasome system (53), but specific features of
LLO that cause it to be a system’s target remained unknown.
Protein substrates of the Ub system, which controls the levels
of many intracellular proteins, are conjugated to Ub through
the action of E1, E2, and E3 enzymes (28, 44, 63). The selec-
tivity of ubiquitylation is mediated largely by E3, which recog-
nizes a substrate’s degradation signal (degron) (7, 22, 60). The
E3 Ub ligases are an exceptionally large family, with more than
1,000 distinct E3s in mammals (4, 13). The term Ub ligase
denotes either an E2-E3 holoenzyme or its E3 component. A
ubiquitylated protein bears a covalently linked poly-Ub chain
and is targeted for processive degradation by the 26S protea-
some (27, 69).
An essential determinant of one class of degrons, called
N-degrons, is a substrate’s destabilizing N-terminal residue.
The set of destabilizing residues in a given cell type yields a
rule, called the N-end rule, which relates the in vivo half-life of
a protein to the identity of its N-terminal residue (see Fig. 1)
(29, 30, 37, 63, 64). In eukaryotes, the N-degron consists of
three determinants: a destabilizing N-terminal residue of a
protein substrate, its internal Lys (K) residue(s) (the site of
formation of a poly-Ub chain), and a conformationally flexible
region(s) in the vicinity of these determinants (7, 31, 47, 64).
The N-end rule has a hierarchic structure in that some of the
destabilizing N-terminal residues (Arg, Lys, His, Phe, Leu,
Trp, Tyr, and Ile) are recognized directly by E3 Ub ligases of
the N-end rule pathway, which are called N-recognins, whereas
the other destabilizing N-terminal residues (Asn, Gln, Asp,
Glu, and Cys) must be modified in vivo, enzymatically or oth-
erwise, for their subsequent recognition by (functionally over-
lapping) N-recognins (see Fig. 1) (2, 29, 30, 36, 64). Physiolog-
ical functions of the N-end rule pathway include its roles in the
control of signaling by nitric oxide (NO) and G protein-cou-
pled receptors, the regulation of peptide import and the fidel-
ity of chromosome segregation, apoptosis, meiosis, cardiovas-
cular development, neurogenesis, and pancreatic functions, as
well as leaf senescence and the auxin transport and signaling in
plants (references 29 and 30 and references therein).
Secreted LLO bears the N-terminal Lys residue, owing to
the removal of the LLO’s signal sequence by a bacterial signal
peptidase during LLO secretion from L. monocytogenes. N-
terminal Lys is a (primary) destabilizing residue in the N-end
rule (see Fig. 1), suggesting that LLO may be a physiological
substrate of the N-end rule pathway in the cytosol of infected
mammalian cells. As shown in the present work, LLO is indeed
an N-end rule substrate. We also found that replacing the
N-terminal Lys of LLO with a stabilizing residue, such as Val,
increased the in vivo half-life of LLO but did not strongly affect
the intracellular growth or virulence of L. monocytogenes. Nev-
ertheless, this replacement decreased the virulence of L.
monocytogenes by nearly twofold, suggesting that a destabiliz-
ing N-terminal residue of LLO may stem from positive selec-
tion during the evolution of this and related bacteria. When
long-lived (mutant) LLO proteins were also overproduced by
L. monocytogenes (owing to a second mutation), the LLO-
mediated toxicity was synergistically and greatly increased. In
summary, the degradation of LLO by the N-end rule pathway
during infection limits the toxicity of overproduced LLO and
may have been selected for its positive effects on fitness during
the evolution of L. monocytogenes.
MATERIALS AND METHODS
Bacterial strains, mammalian cell lines, and reagents. Bacterial strains used in
this study are described in Table 1. All strains were derivatives of the strepto-
mycin-resistant L. monocytogenes strain 10403S of serotype 1/2a (11). To con-
struct LLOWT and LLOK25X mutant strains, the NodI/PstI fragment containing
the LLO-encoding hly gene, including its promoter and the full-length 5 and 3
untranslated regions, was subcloned from pPL1 into the integration vector pPL2
(38). Changes to residue K25 were made by site-directed mutagenesis by using
standard methods (6). The codon for the (wild-type) Lys residue, at position 1 of
the secreted (signal sequence-lacking) LLO, was converted into codons for the
following alternative residues: Arg (AGA), Gly (GGT), Val (GTT), Leu (TTA),
Phe (TTT), Ala (GCA), and Thr (ACA). For each mutation, the most abundant
L. monocytogenes codon, according to the codon usage table from the Kazusa
Research Institute (http://www.kazusa.or.jp/codon/), was used. The constructs
(verified by DNA sequencing) were introduced into Escherichia coli SM10 and
conjugated into the L. monocytogenes hly strain DP-L2161 and the hly actA
strain DP-L4813 (Table 1). The resulting L. monocytogenes strains, containing
single-copy integrated plasmids, were verified by PCR using the primer pairs
PL102/PL95 and PL93/PL95 (38) and were maintained on selective antibiotic-
brain heart infusion (BHI) plates. L. monocytogenes DP-L4813 was produced via
allelic exchange by deleting codons encoding residues 7 to 633 of ActA in strain
DP-L2161 by using the plasmid pDP-3076 (58). For mammalian cell infection
experiments, L. monocytogenes strains were grown without agitation in slanted
15-ml conical tubes overnight at 30°C in BHI broth and washed twice in phos-
phate-buffered saline (PBS) before infection.
The mouse J774 macrophage cell line was grown at 37°C and 5% CO2 in
Dulbecco modified Eagle medium (DMEM) with a high glucose content
(GIBCO/Invitrogen, Carlsbad, CA) and with 7.5% fetal bovine serum (FBS;
GemCell, Woodland, CA) and 2 mM glutamine. Mouse L2 fibroblasts were
grown as described previously (59). NIH 3T3 cells were grown in DMEM with a
high glucose content and 7% FBS (HyClone, Logan, UT). All reagents were
purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise noted. The
proteasome inhibitors N-acetyl-L-leucyl-L-leucyl-L-norleucine (LLnL) and
MG132 were purchased from Calbiochem (San Diego, CA).
TABLE 1. Constructs and L. monocytogenes strains used
for this study
LLO
proteina
LLO
plasmidb
LLO plasmid L. monocytogenes
strain in background:
hlyc
(DP-L2161)
actA hly
(DP-L4813)
Wild type DP-E4817 DP-L4818 DP-L4896
K25R DP-E4861 DP-L4928 DP-L4882
K25G DP-E4874 DP-L4929 DP-L4899
K25V DP-E4875 DP-L4930 DP-L4900
K25L DP-E4876 DP-L4931 DP-L4901
K25F DP-E4995 DP-L4997 DP-L4996
K25A DP-E4880 DP-L4933 DP-L4905
K25T DP-E4879 DP-L4934 DP-L4903
S44S DP-E4878 DP-L4966
K25R S44S DP-E4912 DP-L4967
K25G S44S DP-E4913 DP-L4968
K25V S44S DP-E4914 DP-L4969
K25L S44S DP-E4915 DP-L4970
K25F S44S DP-E4921 DP-L4971
K25A S44S DP-E4961 DP-L4978
K25T S44S DP-E4962 DP-L4979
a Mutant proteins are identified by their mutations.
b DP-E numbers indicate pPL2-LLO constructs in E. coli.
c Reference 32.
5136 SCHNUPF ET AL. INFECT. IMMUN.
 at CALIFO
RNIA INST O
F TECHNO
LO
G
Y on M
arch 14, 2008 
iai.asm
.org
D
ow
nloaded from
 
Plasmids encoding Ub-LLO fusions. The pcDNA3-fDHFR-UbR48-X-LLO1–417-
Flag2 plasmid constructs encoded the previously described (39, 60) fDHFR-
UbR48 moiety (Flag-tagged mouse dihydrofolate reductase [fDHFR] followed by
a mutant Ub moiety containing residue R48 [UbR48]) fused to the mature (signal
sequence-lacking) LLO protein that also lacked its C-terminal (membrane-in-
teracting) domain 4. In the plasmid designation, X denotes a junctional amino
residue of the LLO moiety that becomes N terminal after cotranslational cleav-
age at the Ub-X junction. In these constructs, X was either Lys, a destabilizing
N-terminal residue of the secreted wild-type LLO, or Gly, a stabilizing residue in
the N-end rule. The plasmids were constructed using PCR by amplifying the
sequence encoding residues 25 to 417 of LLO (LLO25-417) from genomic DNA
of L. monocytogenes and using the primers that made the resulting fragment to
encode the Flag epitope as well. The following primers were used: JZ004 (for-
ward primer for the sequence encoding LLO with residue K25 [LLOK25]), 5
ATT TCA CCC GGG AAG GAT GCA TCT GCA TTC AAT AAA GAA AAT
TCA ATT TCA TCC 3; JZ006 (forward primer for the sequence encoding LLO
with the K25G mutation [LLOK25G]), 5 ATT TCA CCC GGG GGC GAT GCA
TCT GCA TTC AAT AAA GAA AAT TCA ATT TCA TCC 3; and JZ008
(reverse primer encoding Flag-tagged LLOG417), 5 ATT TCT AGA GCC GCT
GCC GCT CTT GTC ATC GTC GTC CTT GTA GTC TCC ATC TGT ATA
AGC TTT TGA AGT TGT TTC AAT ATA TTC TGA 3 (restriction sites are
italicized; the codons for the N-terminal residue of LLO and the Flag sequence
are underlined). The PCR-produced DNA fragments were verified by sequenc-
ing and then digested with SmaI and XbaI and ligated into the SmaI/XbaI-cut
plasmid pcDNA3-fDHFR-UbR48-M-cMos (56), replacing the open reading
frame encoding Met–Flag-tagged c-Mos. A second Flag-encoding sequence at
the 3 end of the resulting LLO construct was then added at the XbaI site.
The plasmid pcDNA3-fDHFR-UbR48-M-cMosf was derived from pcDNA3-
fDHFR-UbR48-M-cMos (56) by introducing a Flag sequence after the XbaI
site through PCR.
Assays with transcription-translation reticulocyte lysate. The TNT quick-
coupled transcription-translation system (Promega, Madison, WI) was a rabbit
reticulocyte lysate premixed with additional components necessary for carrying
out transcription and translation in the lysate, including a mixture of amino acids
other than Met. [35S]methionine (1,000 Ci/mmol; Amersham Pharmacia Bio-
tech, Piscataway, NJ) was added to label newly synthesized proteins in reaction
mixtures. Reactions were set up according to the manufacturer’s instructions and
were carried out at 30°C for 1 h, followed by the addition of 1 volume of 2
sample buffer (100 mM Tris-HCl, pH 6.8, 4% sodium dodecyl sulfate [SDS], 20%
glycerol, 0.72 M -mercaptoethanol, 0.1% bromophenol blue), heating at 95°C
for 5 min, 10% SDS-polyacrylamide gel electrophoresis (PAGE), and autora-
diography. Dipeptides were added to the final concentration of 1 mM. Stock
solutions of dipeptides were 0.2 M in PBS containing 0.15 mM bestatin (Sigma).
Pulse-chase and Western analysis with LLO-transfected NIH 3T3 cells.
Mouse NIH 3T3 cells grown to 60% confluence were transfected with
pcDNA3-UbR48-X-LLO25–415-Flag2 or with the control plasmid pcDNA3 or
pcDNA3-fDHFR-UbR48-R-nsP4 (56). For pulse-chase analysis, the medium was
replaced with serum-free and methionine/cysteine-free DMEM after 16 h and
cells were labeled for 10 min with 35S protein-labeling mixture (PerkinElmer,
Wellesley, MA) and then chased in DMEM with 10% FBS for 1 or 2 h. Cells
were lysed in a mixture of 1% Triton X-100, 10% glycerol, 0.15 M NaCl, 5 mM
Na-EDTA, and 20 mM Na-HEPES (pH 7.5) also containing 0.5 mM phenyl-
methylsulfonyl fluoride (PMSF) and protease inhibitor cocktail (Roche, Pleas-
anton, CA). The resulting extracts were clarified by centrifugation at 16,000  g
for 15 min, and samples of the supernatants (containing equal amounts of 35S)
were processed for immunoprecipitation with anti-Flag beads (Sigma). Immu-
noprecipitated proteins were fractionated using 10% SDS-PAGE, followed by
autoradiography and quantitation with a PhosphorImager (Molecular Dynamics,
Sunnyvale, CA). For Western blot analysis, cells were transfected for 24 h and
then incubated with or without the proteasome inhibitor MG132 (50 M) for 4 h.
Next, cells were washed three times with PBS and then lysed in NP-40 lysis buffer
(25 mM Tris [pH 7.5], 1 mM EDTA, 0.1 mM EGTA, 5 mM MgCl2, 1% NP-40,
10% glycerol, 150 mM NaCl, 0.5 M PMSF, and 1 protease inhibitor cocktail
[Roche, Mannheim, Germany]). The extracts were mixed with 2 sample buffer,
boiled for 8 min, clarified by a 5-min spin at 16,000  g, resolved on an 8%
SDS-PAGE gel, transferred onto nitrocellulose, and then probed with polyclonal
anti-LLO antibody.
N-terminal sequencing of secreted LLO proteins. L. monocytogenes strains
secreting either LLOK25R, LLOK25V, or LLOK25G were grown to mid-logarith-
mic phase in Luria-Bertani (LB)-G1P medium (LB medium containing 25 mM
glucose-1-phosphate, 5% activated charcoal, and 50 mM MOPS [morpholinepro-
panesulfonic acid], pH 7.4), and culture supernatants were precipitated with 10%
trichloroacetic acid, washed with acetone, solubilized in SDS-sample buffer, and
fractionated using 4 to 12% gradient bis-Tris SDS-PAGE gels (NuPage; Invitro-
gen). Proteins were transferred onto polyvinylidene difluoride membranes by
electroblotting in CAPS buffer {10% methanol–10 mM CAPS [3-(cyclohexyl-
amino)-1-propanesulfonic acid] adjusted to pH 11 with NaOH} using a semidry
gel blotter (Bio-Rad, Hercules, CA). Membranes were then stained with Coo-
massie blue, and the band corresponding to LLO was excised and processed for
N-terminal sequencing (first three residues) at the Molecular Structure Facility
(University of California, Davis).
Intracellular growth of L. monocytogenes in J774 macrophages and NIH 3T3
cells. Growth curves of L. monocytogenes were determined as previously de-
scribed (46). Cells were infected at an effective multiplicity of infection of 0.1
(J774 macrophages) or 0.01 (NIH 3T3 cells). Gentamicin at 50 g/ml was added
at 1 h (J774 macrophages) or 1.5 h (NIH 3T3 cells) postinfection (p.i.) for the
duration of the experiment. The proteasome inhibitor LLnL (20 M) was added,
when indicated, at 3 h p.i.
Pulse-chase analysis of LLO produced during intracellular growth of L. mono-
cytogenes. The metabolic labeling of bacterial proteins with [35S]methionine dur-
ing the infection of J774 macrophages was based on the method of Moors et al.
(41). J774 cells (2.2  106) were seeded onto 60-mm tissue culture dishes in
DMEM and were infected the next day with an overnight (stationary-phase)
culture of L. monocytogenes for 30 min at a multiplicity of infection of 1. Infected
J774 cells were washed three times with PBS, after which DMEM and also, 30
min later, gentamicin (to 10 g/ml) was added. At 4.5 h p.i., the medium was
changed for 30 min to methionine-free (starvation) DMEM containing 2 mM
Gln, 10% dialyzed FBS, 225 g of cycloheximide/ml, and 30 g of anisomycin/ml.
Thereafter, cells were labeled for 1 h in 0.5 ml of the same medium with 0.2 mCi
(per plate) of the 35S protein-labeling mixture (PelkinElmer). In some experi-
ments, the proteasome inhibitor LLnL was included at 50 M in both starvation
and labeling media. After 1 h, the labeling medium was replaced with chase
medium (DMEM, 7.5% FBS, 2 mM Gln or 20 g of chloramphenicol/ml, 5 mM
Met). At the times indicated below, cell monolayers were washed three times
with cold PBS and lysed by the addition of 1 ml of KD lysis buffer (2% Triton
X-100, 0.02% saponin, 10 mM EDTA, PBS without Mg2 or Ca2) containing
protease inhibitors (1 mM PMSF, 0.3 M aprotinin, 1 M leupeptin, and 1 M
pepstatin A). Both bacteria and insoluble mammalian cell contents were re-
moved by a 10-min spin at 16,000  g. Supernatants were immunoprecipitated
with anti-LLO monoclonal antibody B3-19 (43) as described previously (12). The
immunoprecipitates were processed (see above) for 7.5% SDS-PAGE, autora-
diography, and the quantitation of LLO bands with a Typhoon phosphorimager
(Amersham Biosciences, Arlington Heights, IL) and ImageQuant software (Mo-
lecular Dynamics). To ensure equivalent levels of infection for all strains, three
12-mm coverslips per dish were included. The coverslips were removed at 4.5 h
p.i. and were used to calculate the number of CFU per dish. In experiments that
involved the dephosphorylation of immunoprecipitated LLOK25G, 20 U of calf
intestinal phosphatase (New England Biolabs, Beverly, MA) was employed as
previously described (12).
Plaque formation in L2 fibroblasts. Plaque formation in mouse L2 fibroblasts
was carried out as previously described (59), and plaques were scored by the
method of Skoble et al. (58). Briefly, L2 fibroblasts grown to confluence in 6-well
tissue culture plates were infected with 0.25 l (per plate) of PBS-washed over-
night cultures of L. monocytogenes. After 1 h, cell monolayers were washed three
times with PBS and the medium was replaced with DMEM agar containing 40 g
of gentamicin/ml, the plates were incubated for 3 days, and plaques were visu-
alized using an additional DMEM agar overlay containing 40 g of gentami-
cin/ml and neutral red (GIBCO/Invitrogen) after incubation for 8 h. The relative
plaque size is reported as a percentage of the wild-type plaque size.
Immunoblotting analysis of LLO. Overnight cultures of L. monocytogenes
were diluted 20-fold in LB medium and incubated with shaking for 2.5 h at 37°C
to mid-logarithmic phase (optical density at 600 nm [OD600] of 0.4). Bacteria
were washed once with PBS and diluted into prewarmed LB medium to an
OD600 below 0.01. At various times postinoculation, 1-ml samples were removed
for OD600 measurements and LLO immunoblotting. The samples were centri-
fuged at 16,000  g for 10 min, and the supernatants were removed and precip-
itated with 10% trichloroacetic acid, washed with acetone, and processed for
SDS-PAGE as described above. Fractionated proteins were electroblotted onto
nitrocellulose membranes, and LLO was detected using a rabbit polyclonal
antibody to LLO (52), horseradish peroxidase-conjugated anti-rabbit immuno-
globulin G (IgG) secondary antibody, and the ECL Plus Western blotting kit
according to the instructions of the manufacturer (Promega). To quantitate band
intensities, parallel samples were resolved by SDS-PAGE and subjected to the
same procedure, except that the secondary antibody was Alexa Fluor goat anti-
rabbit antibody (Invitrogen), followed by analysis with an Odyssey infrared im-
ager (LI-COR Biosciences, Lincoln, NE).
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Mouse infections. Cultures of L. monocytogenes strains encoding the LLO
proteins indicated below were prepared in BHI medium as previously described
and stored at 	80°C (52). On the day of inoculation, the samples were thawed
at room temperature and the strains were subcultured into BHI medium and
grown to mid-logarithmic phase at 37°C with agitation. Bacterial cultures were
washed once with PBS and diluted in PBS to 5  106 bacteria per ml. Samples
containing 106 bacteria were injected into 7-week-old female BALB/c mice via
the tail vein. Animals were sacrificed 24 h after inoculation. The livers and
spleens were homogenized in 0.2% saponin, and the level of viable bacteria in
each organ was determined by plating samples of homogenates onto LB plates.
Competitive indices for wild-type 10403S L. monocytogenes versus hly bacteria
expressing LLOK25X (where X is the N-terminal replacement residue) from an
integrated plasmid harboring a chloramphenicol resistance gene were deter-
mined essentially as described in reference 5. In this assay, the L. monocytogenes
hly deletion strain that was complemented with wild-type LLO (L. monocytogenes
LLOWT) had a minor virulence defect compared to 10403S. The ratios of bac-
teria of LLOK25X-expressing strains to 10403S bacteria were determined by
plating organ homogenates onto LB plates and then patching 100 colonies onto
chloramphenicol (20-g/ml)-containing plates. The 50% lethal dose (LD50) of
each L. monocytogenes strain for BALB/c mice was determined by Cerus Phar-
maceuticals (Concord, CA) essentially as previously described (46) except that
mice were injected with twofold dilutions and monitored for 7 days postinocu-
lation.
RESULTS
LLO is a substrate of the N-end rule pathway. Mammalian
reticulocytes (immature red blood cells) and their ATP-sup-
plemented lysates contain an active Ub system including the
N-end rule pathway (15, 26, 48). We asked whether LLO with
the wild-type N-terminal residue Lys (Lys-LLO; derived from
a Ub–Lys-LLO fusion) would be an N-end rule substrate in
reticulocyte lysate. Our experiments utilized the Ub fusion
technique (65), which makes it possible to engineer any protein
to be expressed, in vivo or in vitro, as a Ub fusion whose
(largely) cotranslational deubiquitylation yields a protein of
interest with a desired N-terminal residue. The N-end rule
pathway can be selectively inhibited in the lysate by the addi-
tion of dipeptides bearing either type 1 or type 2 destabilizing
N-terminal residues. Through their interaction with, respec-
tively, type 1 and type 2 substrate-binding sites of the ubiquitin-
protein ligase E3 component N-recognin UBR1 and other
N-recognins (see the introduction; also Fig. 1), such dipeptides
act as specific competitive inhibitors of the N-end rule pathway
(15, 26, 48). Since Lys, the N-terminal residue of wild-type
LLO, is a type 1 primary destabilizing residue (Fig. 1), the
degradation of Lys-LLO in reticulocyte lysate would be ex-
pected to be inhibited by a dipeptide such as, e.g., Arg-Ala,
which bears a type 1 destabilizing N-terminal residue, but not
by, e.g., Ala-Arg.
A transcription-translation reticulocyte lysate (see Materials
and Methods) was used to express Lys-LLO25–415 (Ub-Lys-
LLO25–415), which differed from wild-type LLO in lacking the
C-terminal membrane-binding domain. These assays (Fig. 2A)
utilized the previously developed Ub-protein-reference (UPR)
technique, which increases the accuracy of such assays by pro-
viding a built-in reference protein (39, 60, 65). This method
employs a linear fusion in which Ub is located between a
protein of interest and a long-lived reference protein moiety,
such as the mouse DHFR. The fusion is cotranslationally
cleaved by Ub-specific deubiquitylating enzymes after the last
FIG. 1. Mammalian N-end rule pathway. (A) N-terminal residues are indicated by single-letter abbreviations for amino acids. The yellow ovals
denote the rest of a protein substrate. C* denotes oxidized N-terminal Cys, either Cys-sulfinic acid [CysO2(H)] or Cys-sulfonic acid [CysO3(H)],
produced in reactions mediated by nitric oxide (NO) and oxygen (O2) or oxygen derivatives, with subsequent arginylation of oxidized Cys by the
ATE1-encoded isoforms of Arg-tRNA-protein transferase (R-transferase). (NO is produced from Arg by NO synthases.) The type 1 and type 2
primary destabilizing N-terminal residues are recognized by multiple E3 ubiquitin ligases (N-recognins) of the N-end rule pathway, including
UBR1 and UBR2. Through their other substrate-binding sites, these E3s also recognize internal (non-N-terminal) degrons in other substrates of
the N-end rule pathway, denoted by a larger oval. The dots after “calpains” refer to the expectation that physiologically relevant N-degrons can
also be produced by intracellular proteases additional to those cited. MetAPs, methionine aminopeptidases; NTAN1, N-terminal asparagine-
specific amidase; Ndt, Nds, and Ndp, tertiary, secondary, and primary N-terminal destabilizing residues, respectively. Modified from Nature (30)
with permission of the publisher. (B) MetAPs remove Met from the N terminus of a polypeptide if the residue at position 2 belongs to the set of
residues shown (64). Reprinted from Nature (30) with permission of the publisher.
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residue of Ub, producing equimolar amounts of the protein of
interest and the reference protein bearing the C-terminal Ub
moiety. The UPR technique can thus compensate for differ-
ences in protein yields and sample volumes and other sources
of sample-to-sample variation (39, 65).
Using the previously described and validated steady-state
assay with reticulocyte lysate (15), we determined the levels of
35S-labeled synthesized Lys-LLO25–415 in the lysate relative to
the levels of the DHFR-Ub reference. In the presence of the
Arg-Ala dipeptide, which bears a destabilizing N-terminal res-
idue of the same (type 1) class as that of Lys-LLO (Fig. 1), the
level of Lys-LLO25-415 in the lysate was much higher than
either in the presence of (compositionally identical) Ala-Arg
or in the absence of added dipeptides (Fig. 2A, lanes 1 to 3). As
expected, Phe-Ala, which contained a type 2 destabilizing N-
terminal residue (Fig. 1), did not increase the levels of Lys-
LLO25-415 (data not shown), in contrast to Arg-Ala. This in-
hibitor-based evidence that 35S-labeled Lys-LLO25-415 in the
lysate was targeted for degradation by the N-end rule pathway
was independently supported by the results of an otherwise
identical assay with Gly-LLO25-415, which differed from Lys-
LLO25-415 solely by its N-terminal residue. (Gly is a stabilizing
residue in the N-end rule [Fig. 1].) In contrast to those of
Lys-LLO25-415, the levels of 35S-labeled Gly-LLO25-415 pro-
duced in reticulocyte lysate were not altered by the addition of
Arg-Ala, thus confirming, in a different way, that Lys-LLO25-415
was degraded by the N-end rule pathway in reticulocyte lysate.
The likely flexibility of LLO’s N-terminal region, as evaluated
by analogy with the similar perfringolysin O toxin of Clostrid-
ium perfringens (49) and the use of Phyre (http://www.sbg.bio
.ic.ac.uk/phyre/) three-dimensional prediction software, pre-
sumably contributes to the targeting of Lys-LLO by the N-end
rule pathway, given the previously established requirement for
a flexible region downstream of a substrate’s destabilizing
N-terminal residue as one determinant of the substrate’s N-
degron (see the introduction).
To verify that Lys-LLO25-415 was degraded by the N-end rule
pathway in vivo as well, mouse NIH 3T3 cells were transiently
transfected with plasmids that expressed either Lys-LLO25-415
or Gly-LLO25-415, the latter bearing a stabilizing N-terminal
residue, with both test proteins produced by deubiquitylation
of their Ub fusions (see above). We analyzed LLO degradation
in NIH 3T3 cells by using both immunoblotting and pulse-
chase assays. In the pulse-chase assays, the band of Gly-LLO25-415
was prominent at the end of the 10-min pulse and remained
undiminished throughout a 2-h chase, whereas the band of
Lys-LLO25-415 was barely detectable (at the same level of au-
toradiographic exposure) even before the chase, i.e., at the end
of the 10-min pulse (Fig. 2C, lanes 2 to 4; compare lanes 5 to
7). While longer exposures than that for the sample shown in
Fig. 2C allowed the detection of the band of pulse-labeled
Lys-LLO25-415, the quantitation of the band patterns con-
FIG. 2. LLO is a substrate of the N-end rule pathway. (A) A plasmid encoding the UPR technique-based fusion comprising fDHFR-UbR48 and
Flag-tagged Lys-LLO25–415 (see Results) was expressed in a transcription-translation rabbit reticulocyte extract in the presence of [35S]methionine
for 1 h at 30°C, after which the extract was analyzed by SDS-PAGE and autoradiography. The above-mentioned fusion was cotranslationally
processed into fDHFR-UbR48 (a long-lived reference protein) and Flag-tagged Lys-LLO25-415 (see Results). Lane 1, results of analysis in the
absence of added dipeptides (	); lane 2, same as lane 1 but in the presence of 1 mM Arg-Ala (RA); lane 3, same as lane 1 but in the presence
of 1 mM Ala-Arg (AR); lanes 4 to 6, same as lanes 1 to 3 but with Flag-tagged Gly-LLO25-415; lanes 7 and 8, same as lanes 1 to 3 but with the
control N-end rule substrate Arg-nsP4, a Sindbis virus RNA polymerase with a destabilizing N-terminal Arg (15, 56). (B) Stabilization of
Flag-tagged Lys-LLO25-415 in mouse NIH 3T3 cells by the inhibition of host proteasomes. The cells were transiently transfected with the plasmid
pcDNA3 or plasmid constructs pcDNA3-UbR48-X-LLO25-415-Flag2 (where X represents Lys or Gly). After 24 h, cells were either left untreated
(	; lanes 1, 3, and 5) or incubated with the proteasome inhibitor MG132 (50 M) for 4 h (; lanes 2, 4, and 6) before cells were lysed and the
extracts were processed for Western blotting with polyclonal anti-LLO antibody. The asterisk (*) indicates nonspecific bands that served as internal
loading controls. (C) Degradation of Flag-tagged Lys-LLO25-415 and Gly-LLO25-415 in mouse NIH 3T3 cells. The cells were transiently transfected
with pcDNA3-UbR48-X-LLO25-415-Flag2 plasmids. Cells were pulse-labeled with [
35S]methionine for 10 min and chased for 1 and 2 h, after which
they were subjected to immunoprecipitation with anti-Flag antibody, SDS-PAGE, and autoradiography. Lane 1, vector alone (control [C]); lanes
2 to 4, cells expressing Flag-tagged Lys-LLO25-415; lanes 5 to 7, cells expressing Flag-tagged Gly-LLO25-415. (D) Quantification of the pulse-chase
patterns in panel B, with the amount of Flag-tagged Gly-LLO25-415 at the end of the pulse taken as 100%.
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firmed the much lower level of pulse-labeled Lys-LLO25-415
than of Gly-LLO25-415 in NIH 3T3 cells, indicating the rapid
degradation of Lys-LLO25-415 during the 10-min pulse, i.e.,
even before the chase (Fig. 2D and data not shown). Interest-
ingly, whereas young (pulse-labeled) molecules of Lys-LLO25-415
were rapidly degraded by the N-end rule pathway in vivo, those
(relatively few) molecules of Lys-LLO25-415 that escaped deg-
radation shortly after their synthesis were degraded at later
times (during the chase) apparently at a much lower rate than
their newly formed (young) counterparts (Fig. 2D). In other
words, the activity of the N-degron of Lys-LLO25-415 appar-
ently decreased as a function of time posttranslation. This
effect, previously observed with other N-end rule substrates
(and substrates of other Ub-dependent pathways as well) is
likely to stem, at least in part, from conformational changes
(conformational maturation) that newly formed proteins un-
dergo soon after their synthesis, including, for oligomeric
proteins, the formation of either homo- or hetero-oligomers
(9, 60).
Without proteasome inhibitors, Lys-LLO25-415 was unde-
tectable by immunoblotting, whereas Gly-LLO25-415 was
readily detectable (Fig. 2B, lanes 3 and 5). In striking contrast,
the level of Lys-LLO25-415 was greatly increased in NIH 3T3
cells after 4 h of treatment with MG132, a proteasome inhib-
itor, whereas the same treatment only marginally increased the
level Gly-LLO25-415 (Fig. 2B, lanes 3 to 6). Taken together, the
above-cited in vitro (Fig. 1) and in vivo (Fig. 2) evidence
identified Lys-LLO25-415 as a substrate of the mammalian N-end
rule pathway. These data also suggest that LLO may contain at
least one other, apparently weaker, degron that is targeted by a
non-N-end rule pathway.
L. monocytogenes strains secreting LLOs with different N-
terminal residues. To examine whether secreted LLOs bearing
either destabilizing or stabilizing N-terminal residues (Fig. 1)
would exhibit different functional properties and result in bac-
teria with different abilities to infect (and grow in) mammalian
hosts, we began by constructing L. monocytogenes strains that
secreted X-LLOs, in which X was either Gly or Val (stabilizing
residues in the N-end rule), Arg (a type 1 destabilizing resi-
due), Leu or Phe (type 2 destabilizing residues), Ala, or Thr.
The latter two N-terminal residues, and Ser as well, can be
destabilizing under certain conditions (26), but the corre-
sponding N-recognin, i.e., an E3 Ub ligase(s) specific for N-
terminal Ala, Thr, and Ser, has not been identified. In addition,
N-terminal Ala, Thr, and Ser residues are often acetylated in
vivo, a modification that would be expected to preclude their
recognition as destabilizing residues.
LLOK25R, LLOK25V, and LLOK25G that were secreted by the
corresponding L. monocytogenes strains were isolated to deter-
mine their N-terminal residues by Edman sequencing (see
Materials and Methods). These tests directly confirmed the
presence of Arg, Val, and Gly, respectively, at the N termini of
the above-listed (mutant) X-LLO proteins, indicating that the
residues that replaced wild-type Lys-25 did not alter the signal
sequence cleavage site of LLO.
Previous work has shown that the 5 untranslated region and
the 5-proximal part of the LLO-encoding hly mRNA are in-
volved in regulating LLO synthesis during growth in vitro and
in mammalian cells as well (52, 55). In particular, a single-
codon change at residue Ser-44 of LLO that retained Ser as the
encoded residue strongly increased LLO production, resulting
in host cell toxicity and intracellular growth and virulence de-
fects (24, 52, 53). To determine whether the above-described
alterations of the N-terminal residue of secreted LLO affect
LLO synthesis, we assayed the relative amounts of mutant
LLOK25X proteins that were produced during the in vitro
growth of the corresponding L. monocytogenes strains. These
tests included the LLOS44S L. monocytogenes mutant that pro-
duces a wild-type LLO but exhibits increased translation of the
LLO mRNA during logarithmic growth (52).
The mutant L. monocytogenes strains grew indistinguishably
from wild-type L. monocytogenes in both LB and BHI broth
(Fig. 3A and data not shown). The relative levels of secreted
LLOK25X proteins (determined by immunoblotting) were sim-
ilar for all of the tested strains at the late stationary phase of
growth in LB broth (Fig. 3B). In addition, all of the mutant
LLOK25X proteins had activities similar to those of pore-form-
ing proteins, as determined by assaying their abilities to lyse
red blood cells (Fig. 3C). Furthermore, the alterations of the
N-terminal residues in LLOK25X proteins did not affect the pH
optimum of LLO (Table 2). There were small differences in
the amounts of secreted LLOK25X proteins during exponential
in vitro growth, although all of the observed differences were
much below the 9-fold overproduction of LLO by the
LLOS44S L. monocytogenes mutant (Fig. 3B). Since the se-
creted LLO is not degraded in the medium during the in vitro
growth of L. monocytogenes (52), the various levels of
LLOK25X proteins produced by exponentially growing cells
were most likely due to (relatively small) alterations in the rate
of LLO synthesis. Thus, the mutational alterations of the N-
terminal residue of the secreted LLO resulted in (at most)
minor changes in the rate of its production and did not alter
the pore-forming activity of LLO (Fig. 3 and Table 2).
Stabilization of LLO against degradation by the N-end rule
pathway has minor effects on the intracellular growth or vir-
ulence of L. monocytogenes. We next examined the ability of the
above-mentioned L. monocytogenes mutants to grow intracel-
lularly in mammalian cells. The rates of growth of the L.
monocytogenes LLOK25X mutants in mouse J774 macrophage-
like cells for the first 8 h were lower than the rate of growth of
the wild-type strain by up to twofold (Fig. 4A). By 11 h p.i.,
the strains expressing LLOK25G, LLOK25V, LLOK25A, and
LLOK25T exhibited a retardation of growth of up to fourfold in
J774 cells (Fig. 4A). The strains expressing LLOK25R,
LLOK25L, and LLOK25F (in which the wild-type destabilizing
Lys residue was changed to another destabilizing residue) con-
tinued to exhibit at most twofold-slower growth than wild-type
L. monocytogenes (Fig. 4A). However, none of the above-listed
LLO mutants had a substantial growth defect in NIH 3T3
fibroblasts (Fig. 4B) or in the (3-day) plaque formation assay,
which integrates both the intracellular growth of L. monocyto-
genes and its ability to infect neighboring cells (Fig. 4C). In
contrast, L. monocytogenes LLOS44S, which expresses strongly
increased levels of LLO, exhibited a 50-fold reduction in
intracellular growth in J774 cells by 8 h p.i. and was unable to
form plaques in L2 cell monolayers (52). Finally, we found that
the L. monocytogenes LLOK25X mutants exhibited close to
wild-type levels of virulence as measured by the LD50s for
BALB/c mice (Table 2), although minor virulence defects (up
to a 1.9-fold reduction) in the liver were detected for the L.
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monocytogenes LLOK25V strain relative to L. monocytogenes
LLOWT when the strains were directly compared to wild-type
L. monocytogenes 10403S in the competitive index assay (see
Fig. 7B and Discussion). Taken together, these results indicate
that while the metabolic stabilization of secreted X-LLO de-
tectably compromised the intracellular growth, cell-to-cell
spread, and virulence of L. monocytogenes, the effects observed
were relatively small (Fig. 3 and 4 and Table 2).
The identity of LLO’s N-terminal residue affects LLO deg-
radation in mammalian cytosol. LLO secreted from L. mono-
cytogenes into the host cell cytosol becomes phosphorylated
and ubiquitylated before its rapid, proteasome-dependent deg-
radation (53). However, LLO secreted during cell-to-cell
spread appears to be proteolytically cleaved but is otherwise
longer lived, suggesting the existence of metabolically distinct
subpopulations of LLO (53). To confine the analysis to LLO
that is degraded in vivo, we introduced the wild-type and
LLOK25X mutant alleles into an L. monocytogenes strain with a
deletion of actA. The actA gene encodes a bacterial protein
required for actin polymerization and the intercellular dissem-
ination of L. monocytogenes (18, 34, 61). The absence of cell-
to-cell spread did not result in a detectable effect on the intra-
cellular growth of L. monocytogenes strains that secreted either
LLOWT or LLOK25X by up to 8 h p.i. (data not shown).
Using pulse-chase analysis, we found that changing the N
terminus of LLO from Lys to Arg, another type 1 primary
destabilizing residue (Fig. 1), did not significantly affect the
rate of LLO degradation (Fig. 5A). In contrast, the placement
of other residues, including stabilizing residues, at the LLO N
terminus led to a strong, up to 10-fold, metabolic stabilization
of X-LLO (Fig. 5A). Stabilized X-LLO migrated as both a
58-kDa band (a species that comigrates with the full-length
LLO minus the signal sequence) and a 60-kDa band. The
latter, in the case of wild-type LLO, was previously shown to be
its phosphorylated derivative (52). In agreement with this con-
clusion, phosphatase treatment shifted the 60-kDa species of
immunoprecipitated LLOK25G to the 58-kDa form (Fig. 5B).
In addition, larger (60-kDa) LLO-containing species, which
were previously shown to be ubiquitylated derivatives of LLO
(53), were also observed (Fig. 5).
For reasons unknown, the replacement of a type 1 destabi-
lizing residue such as Lys by a type 2 destabilizing residue such
as Phe or Leu at the N terminus of LLO significantly stabilized
the resulting X-LLO during the chase (Fig. 5A). However, the
initial (postpulse) levels of Phe-LLO and Leu-LLO were lower
than those of their counterparts in the case of, for example,
Thr-LLO and Gly-LLO (Fig. 5A). These data are in agreement
FIG. 3. Secretion of LLO bearing different N-terminal residues by
L. monocytogenes strains growing outside host cells. (A and B) Growth
(A) and LLO secretion (B) in LB medium by L. monocytogenes strains
that produced either wild-type (WT) Lys-LLO or its derivatives con-
taining other (indicated) N-terminal residues. The relative amounts of
secreted X-LLO proteins (in mid-logarithmic [mid log], late-logarith-
mic [late log], and stationary [stat] phases of growth) were compared
by immunoblotting. Shown are the results of one of five independent
experiments. The numbers below the first row in panel B (which
include standard deviations) refer to the quantitation of immunoblots
from three samples taken during mid-exponential growth and analyzed
with an Odyssey infrared imager. (C) Hemolytic activity of LLO
present in stationary-phase culture supernatants from the L. monocy-
togenes strains with the indicated mutations. Error bars indicate stan-
dard deviations for three replicates in one experiment that is repre-
sentative of four independent experiments. sRBCs, sheep red blood
cells.
TABLE 2. Hemolytic activity ratios and LD50s of L. monocytogenes
LLO strains
Straina
Hemolytic activity
ratio (dilution at
pH 5.5/dilution
at pH 7.4)b
LD50c
Wild type 9.5 4.2  104
K25R 9.7 4.8  104
K25G 11.3 5.3  104
K25V 10.5 4.7  104
K25L 11.1 UD
K25F 11.9 3.5  104
K25A 11.3 3.7  104
K25T 11.5 UD
a Mutant strains are identified by the mutations in their LLOs.
b Ratio of the dilutions of supernatants from L. monocytogenes strains grown
in LB broth to late stationary phase required for 50% lysis of sheep red blood
cells when assayed at pH 5.5 and 7.4.
c The LD50s were determined by injecting 6-week-old female BALB/c mice
with twofold dilutions via the tail vein and monitoring the mice for 7 days. UD,
undetermined.
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with the observed decrease in LLO production during the in
vitro growth of L. monocytogenes, i.e., in the absence of host
cells (Fig. 3B). Indeed, when the degradation of secreted X-
LLO in the mouse cell cytosol was inhibited, during pulse-
labeling, by the proteasome inhibitor LLnL, the relative levels
of pulse-labeled X-LLOs closely corresponded to those ob-
served during the exponential growth of L. monocytogenes in
the absence of host cells (Fig. 5C and 3B). Taken together, the
patterns of X-LLO degradation in reticulocyte extract and in
mouse NIH 3T3 cells (Fig. 2), as well as the degradation
patterns of secreted X-LLO in the host cytosol (Fig. 5A), were
a (qualitatively) self-consistent set, demonstrating directly that
wild-type LLO, bearing N-terminal Lys, is a physiological sub-
strate of the N-end rule pathway.
Synergistic impairment of intracellular growth of L. mono-
cytogenes by a combination of overproduction and metabolic
stabilization of LLO. Our previous work has shown that a
higher rate of LLO production is synergistically cytotoxic with
the metabolic stabilization of LLO, the latter achieved by the
pharmacological inhibition of the proteasome (24, 52, 53).
Specifically, treatment with a proteasome inhibitor has negli-
gible effects on the intracellular growth of wild-type L. mono-
cytogenes, but the same treatment results in high LLO-medi-
FIG. 4. Alterations of LLO’s N-terminal residue have at most weak
effects on the intracellular growth of L. monocytogenes. (A and B)
Growth curves of L. monocytogenes LLOWT (WT; expressing Lys-
LLO) and LLOK25X mutants (identified by the corresponding muta-
tions) in J774 macrophages (A) and NIH 3T3 fibroblasts (B) (see
Materials and Methods). Shown here are the results, including stan-
dard deviations, of one of at least three independent experiments with
triplicate coverslips for each experiment. The P values for the growth
difference between the LLOWT and LLOK25X strains of L. monocyto-
genes were 0.008 and 0.035 at 8 and 11 h p.i., respectively (based on
Student’s t test for one sample; http://www.statpages.org). (C) Sizes of
plaques formed in mouse L2 fibroblasts by L. monocytogenes strains
that produced the indicated X-LLO proteins relative to the size of
plaques formed by the wild-type strain expressing Lys-LLO, which was
set as 100%. Standard deviations were compiled from the results of
three independent experiments.
FIG. 5. Alterations of LLO’s N-terminal residue affect its degrada-
tion in the host cell cytosol. (A) Pulse-chase analysis of X-LLO pro-
teins (where X is Lys [wild type], Arg, Leu, Phe, Ala, Thr, Gly, or Val).
X-LLOs were immunoprecipitated from extracts of J774 macrophages
that were infected with nonspreading (actA) L. monocytogenes strains
secreting the indicated X-LLO proteins. P and C in panel A refer to
pulse and chase, respectively. Cells were labeled at 5 h p.i. for 1 h with
[35S]methionine and, when indicated, chased for 30 min, after which
they were subjected to immunoprecipitation with anti-LLO antibody,
SDS-PAGE, and quantitation (see Materials and Methods). The band
intensities after the chase, relative to those immediately after the
pulse, were used to estimate the approximate half-lives (T1/2) of X-
LLO proteins. Shown are the results from one of two independent
experiments. WT, wild type. (B) Immunoprecipitated LLOK25G (Gly-
LLO; lane 1) was incubated either with buffer only (lane 2) or with
buffer containing calf intestinal phosphatase (CIP; lane 3) for 20 h at
37°C prior to SDS-PAGE (lane 3). (C) X-LLOs with the indicated
mutations were labeled with [35S]methionine at 5 h p.i. for 30 min in
the presence () of LLnL (see Materials and Methods). rel. levels,
relative levels.
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ated toxicity when combined with mutations that increase the
rate of LLO synthesis and secretion (52, 53). These results
suggested that the proteasomal degradation of LLO becomes
critical for intracellular growth when LLO is synthesized at
higher-than-wild-type levels. To address these issues by stabi-
lizing X-LLO through changes of its N-terminal residue (in-
stead of a much less specific, metabolically pleiotropic inhibi-
tion of the proteasome), we constructed a panel of L.
monocytogenes strains that combined alterations of the N-ter-
minal residue of secreted LLO with the synonymous codon
change at residue S44 that increases the rate of LLO produc-
tion and secretion into the host cytosol at the level of LLO
translation during cytosolic growth (52).
The analysis of the resulting double mutant bacteria re-
vealed strikingly high levels of X-LLO toxicity (up to a 100-fold
reduction in growth over 8 h p.i) when the S44S mutation was
combined with a stabilizing N-terminal residue (Fig. 6).
Through visual monitoring of the infection, it was clear that the
observed synergistic growth defect of the K25X-S44S double
mutants stemmed, in a large part, from their toxicity to the
infected host cell (data not shown). Under the conditions of
our assay, this toxicity was manifested as an increase in plasma
membrane permeability. The increased permeability reduced
the number of CFU through the influx of the bactericidal
antibiotic gentamicin from the medium into the host cell, the
lysis of the host cell, and the subsequent exposure of the bacteria
to gentamicin in the medium. When a change of the N-terminal
residue of LLO reduced the production of LLO both in vitro
(in the absence of host cells) and during intracellular growth
(Fig. 3B and 5C), the degree of synergism between a (partially)
stabilizing N-terminal alteration and the S44S mutation was
also reduced (K25F and S44S) or lacking altogether (K25L and
S44S) (Fig. 6). We conclude that LLO-mediated toxicity de-
pends on the rates of both the production and degradation
of LLO.
To explore further the effects of LLO degradation by the
N-end rule pathway on the virulence of L. monocytogenes, we
analyzed the S44S mutant and the K25X-S44S double mutants
in the murine model of listeriosis (Fig. 7A and Materials and
Methods). Strikingly, the levels of CFU of each L. monocyto-
genes mutant recovered from the spleens of infected mice
strongly correlated with the observed growth defects of the
corresponding mutant in the J774 macrophage cell culture
model. Specifically, the replacement of the (wild-type) N-ter-
minal Lys residue of LLO by stabilizing residues strongly in-
creased the virulence defect of L. monocytogenes LLOS44S in
BALB/c mice, up to 100-fold after 24 h p.i. (Fig. 1, 6, and 7A).
A similar pattern in the livers of infected mice was observed
(Fig. 7A). While an effect of metabolically stabilized LLOK25V
on the virulence of the corresponding single-mutant strain
appeared to be lacking when measured by the LD50 for
BALB/c mice (Table 2), an up to nearly twofold decrease in
virulence in the liver could be reproducibly detected using the
competitive index assay (Fig. 7B) and is briefly considered
below.
DISCUSSION
LLO that is secreted into the host cell cytosol during the
intracellular growth of L. monocytogenes is phosphorylated,
ubiquitylated, and rapidly degraded by the Ub-proteasome sys-
tem (53, 68). In this study, we employed reverse-genetic and
pharmacological techniques to directly demonstrate that se-
creted LLO, which bears N-terminal Lys, a type 1 destabilizing
residue in the N-end rule (Fig. 1), is a physiological substrate
of the N-end rule pathway (Fig. 2–5). In particular, the meta-
bolic stability of LLO, in reticulocyte extract, in mouse NIH
3T3 cells, and in the cytosol of infected mouse cells, depended
on the identity of the N-terminal residue of LLO, with stabi-
lizing residues, such as Gly and Val, strongly inhibiting LLO
degradation (see Results).
The N-end rule pathway is a Ub-dependent proteolytic path-
way that is present in all eukaryotes examined (Fig. 1 shows the
pathway’s diagram; see also the introduction). Replacing the
N-terminal Lys of LLO with a stabilizing residue such as Val
increased the in vivo half-life of LLO but did not strongly affect
the intracellular growth or virulence of L. monocytogenes. This
finding suggests that the rapid degradation of LLO by the
N-end rule pathway is not a primary mechanism to control
LLO activity in the host cytosol. However, our previous work
has shown that a combination of pharmacological inhibition of
the proteasome-dependent degradation of LLO and a muta-
tion in LLO that increases the rate of its synthesis is synergis-
tically cytotoxic to infected mouse cells, implying that the in
vivo degradation of secreted LLO is functionally relevant (53).
In the present study, we also found that double mutant L.
monocytogenes strains in which upregulated secretion of LLO
was combined with the presence of a stabilizing residue (such
as Gly or Val) at the LLO N terminus were synergistically and
severely cytotoxic to infected mammalian cells, a property that
FIG. 6. Synergistic effects of both overproducing LLO and increas-
ing its in vivo half-life on the intracellular growth of L. monocytogenes
in mouse cells. Graphs depict the intracellular growth, in J774 macro-
phages, of L. monocytogenes strains that overproduced LLO (owing to
the LLOS44S mutation) and, when indicated, also contained mutational
alterations of the N-terminal residue of LLO (K25X). See Materials
and Methods for technical details. Error bars indicate standard devi-
ations of results for triplicate coverslips from one experiment repre-
sentative of three independent experiments.
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reduced the ability of the bacteria to grow intracellularly and
resulted in a 100-fold decrease in virulence. Thus, the deg-
radation of LLO by the N-end rule pathway can, in principle,
function as a backup mechanism to control the pore-forming
activity of LLO and to protect the intracellular niche of L.
monocytogenes when LLO is overproduced during the cytosolic
growth of L. monocytogenes.
The secretion of specific protein effectors into the cytosol of
eukaryotic host cells is a widespread strategy of bacterial
pathogens. These bacterial effectors are important virulence
factors that can perturb a wide variety of host processes such as
phagocytosis, apoptosis, vesicular trafficking, and the innate
immune response to infection (8, 17, 21, 42). The role and
importance of the host’s degradative machinery in the control
of the function of these microbial effectors are becoming in-
creasingly clear (3). For example, the invasion of epithelial
cells by Salmonella enterica serovar Typhimurium requires
the reversible activation of host Rho family GTPases by the
bacterial guanine nucleotide exchange factor SopE and the
GTPase-activating protein Spt. To temporally regulate their
opposing functions, these two proteins utilize different rates of
degradation by host proteasomes (35). Another type III effec-
tor recently identified to be ubiquitylated and degraded by the
host proteasome pathway is the GTPase-activating protein
YopE from Yersinia enterocolitica (50). The stabilization of
YopE by the pharmacological inhibition of host proteasomes
FIG. 7. Metabolic stabilization of LLO decreases the virulence of L. monocytogenes in mice. (A) BALB/c mice were inoculated, by tail vein
injection, with 106 bacteria of the L. monocytogenes strains with the indicated mutations. All bacteria contained the LLO S44S mutation that results
in the overproduction of LLO and, in addition, either the wild-type N-terminal Lys residue of LLO or its replacement residue, as shown. CFU were
recovered from the livers and spleens 24 h postinoculation by plating dilutions of organ homogenates onto LB plates. Values shown represent the
pooled data from at least three independent experiments, with five mice per strain of L. monocytogenes. Black horizontal bars indicate median
values for each data set. (B) Competitive indices of L. monocytogenes 10403S versus the complemented hly deletion strains expressing either
wild-type LLO or LLOK25V. A 1:1 mixture of complemented hly L. monocytogenes and wild-type 10403S L. monocytogenes was coinjected into
the tail veins of BALB/c mice. The ratio of each strain in the livers and spleens was determined by plating organ homogenates and subsequently
screening 100 colonies for the chloramphenicol resistance phenotype of the complemented strain. The P values indicated were obtained with
Student’s t test for two samples (http://www.statpages.org).
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led to an increase in the activity of its target GTPase, Rac, and
a cytotoxic effect of YopE on the host cell (50).
A cytolysin such as LLO faces conflicting design specifica-
tions in its metabolic stability and other properties. For exam-
ple, the secreted LLO should be able to form pores in the
membrane of a macrophage’s phagosome, thereby making pos-
sible the escape of L. monocytogenes into the cytosol. However,
once the bacterium finds itself in the cytosol, excessive activity
of secreted LLO would lead to pores in the plasma membrane,
an alteration that can be directly cytotoxic to the host cell,
resulting in the loss of the protective intracellular niche and the
exposure of the bacteria to the hostile environment of the
extracellular milieu. To balance these (and other) conflicting
requirements, the evolutionary pressures that yielded the cur-
rent L. monocytogenes LLO have made it much more active at
the relatively low pH of phagosomes than at the near-neutral
pH of the cytosol (25, 54). LLO is also a short-lived protein in
the cytosol, being targeted, as shown in the present study, by
the N-end rule pathway. The rates of synthesis and secretion of
LLO by L. monocytogenes are also regulated by the bacterium’s
specific environment in ways that are still largely unexplored
(10, 14, 52, 55).
Our demonstration that the (mutational) stabilization of
LLO against targeting by the N-end rule pathway does not, by
itself, have strong effects on physiological aspects of the growth
and virulence of L. monocytogenes raises the question of how
this regulatory mechanism is maintained. It should be noted
that although the replacement of the N-terminal Lys residue of
LLO with a stabilizing residue such as Val did not strongly
affect the intracellular growth or virulence of L. monocyto-
genes, this replacement did decrease the virulence of L. mono-
cytogenes by nearly twofold (Fig. 7B), suggesting that a desta-
bilizing N-terminal residue of LLO may stem from positive
selection during the evolution of this and related bacteria.
Long-term evolutionary selection usually operates on marginal
differences in fitness. In other words, it is possible, indeed
likely, that the relative smallness of the physiological effects
that result from the metabolic stabilization of LLO and the
short-term nature of laboratory-based tests may not suffice to
detect the evolutionary relevance of such effects under condi-
tions of long-term selection of bacteria in their natural habi-
tats. Thus, moderate (even weak) but long-term selection pres-
sures may account, at least in part, for the observed
degradation of the secreted L. monocytogenes LLO by the
N-end rule pathway.
The physiological significance of LLO degradation may also
vary for different L. monocytogenes strains. The N-terminal Lys
residue of LLO, a primary destabilizing residue in the N-end
rule (Fig. 1), is conserved in the 150 quasi-independent iso-
lates of L. monocytogenes in which the LLO-encoding gene hly
has been sequenced (P. Schnupf and D. A. Portnoy, unpub-
lished data). In addition, the predicted N-terminal Asp residue
of secreted ivanolysin O, an LLO-like cytolysin from patho-
genic L. ivanovii, is also a destabilizing residue in the N-end
rule (Fig. 1). However, 63% of the hly sequences displayed
changes in more than 40 nucleotides compared to the hly
sequence of our wild-type L. monocytogenes strain 10403S (as
well as that of the other commonly used wild-type strain, EGD-
e). Furthermore, more than 50% of the available hly sequences
displayed between one and six nucleotide changes compared to
the wild-type sequences within the first 52 codons, a region
previously shown to restrict the translation of LLO during the
cytosolic growth of L. monocytogenes (52). These nucleotide
changes were predominantly in codons 14, 18, 19, 26, 31, 35,
and 39 (and combinations thereof). Because a nucleotide
change in codon 44 can result in a dramatic increase in LLO
production during the cytosolic growth of L. monocytogenes
and a severe virulence defect (24, 52, 53), the identified se-
quence divergence within the 5 region of hly among the clin-
ical isolates may contribute to differences in the translational
control and hence the production of LLO during the cytosolic
growth of the bacteria. Alternatively, because many of the
nucleotide changes also resulted in amino acid changes, strain
differences in the LLO protein may affect the pH optimum
and/or protein-protein interactions that may keep LLO inac-
tive in the host cytosol. Thus, strain variations in the produc-
tion and the activity of the LLO protein are two other possible
means by which selective pressure for LLO degradation may
be maintained.
One functionally relevant aspect of the metabolic instability
of LLO is that the immunodominant LLO peptide comprising
residues 91 to 99 (peptide 91-99) becomes presented on major
histocompatibility complex class I molecules on the surfaces of
infected cells, where it is recognized by cytotoxic T cells (19).
When host proteasomes are inhibited, the presentation of LLO
peptide 91-99 is blocked (67, 68). While it is still unknown
whether the in vivo half-life of secreted LLO influences the
presentation of LLO peptide 91-99, it was previously shown
that the proteasome-dependent degradation of another se-
creted L. monocytogenes protein, called p60 (a cell wall hydro-
lase and a prominent antigen of L. monocytogenes), facilitates
the presentation of its major histocompatibility complex class I
epitope (57).
It should be noted that the secreted p60 protein, which bears
N-terminal Ser and has a moderately short in vivo half-life of
75 min (57), is not a substrate of the N-end rule pathway as
it is understood at present (Fig. 1). The same is true for ActA,
another secreted L. monocytogenes protein, which bears N-
terminal Ala (40). While early work (26) indicated that other-
wise-identical reporter proteins bearing N-terminal Ala, Ser,
and Thr residues were shorter lived than those bearing stabi-
lizing N-terminal residues such as Gly and Val, subsequent
attempts to identify an E3 Ub ligase(s) that recognizes the
above-mentioned N-terminal residues have not been successful
thus far. In addition, the N-terminal Ala, Ser, and Thr are
acetylated in many proteins that bear such residues, further
complicating the disposition. Both ActA and p60 can be made
much shorter lived than their wild-type counterparts by con-
verting their N-terminal Ala and Ser, respectively, into desta-
bilizing residues of the currently known N-end rule pathway
(Fig. 1) (40, 57). However, for the reasons given above, that
fact by itself is insufficient for concluding, as yet, that the in
vivo degradation of wild-type ActA and p60 involves the spe-
cific recognition of their N-terminal residues by a (presumed)
E3 Ub ligase(s). The secreted LLO protein which bears N-
terminal Lys, a type 1 destabilizing residue (Fig. 1), is thus, at
present, the sole bona fide N-end rule substrate among the
secreted proteins of L. monocytogenes.
In summary, the pore-forming activity of LLO must be
tightly regulated to prevent host cell lysis during cytosolic
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growth (16, 24, 25, 52). Two previously described posttran-
scriptional mechanisms that limit LLO-mediated toxicity to the
host cell are the control of LLO synthesis in the host cell
cytosol by the negative regulation of LLO translation (52) and
the decreased activity of LLO at the neutral pH of the cytosol
(a low-pH optimum of LLO) (25). As shown above, the deg-
radation of LLO by the host’s N-end rule pathway is yet an-
other postranscriptional mechanism of LLO regulation that
can limit LLO-mediated toxicity and may have been selected
for its positive effects on fitness during the evolution of L.
monocytogenes.
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